Design Therapeutics grants director 30,000 stock options

Design Therapeutics, Inc. director David Shapiro received a stock option grant covering 30,000 shares of common stock.

Rhea-AI Filing Summary

Design Therapeutics, Inc. director David Shapiro received a stock option grant covering 30,000 shares of common stock. The option has an exercise price of $10.55 per share and expires on June 8, 2036. The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026, and will in any case be fully vested by the date of the company’s next annual meeting of stockholders. This is a compensation-related award, not an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 30,000 shares

Grant/Award 1 txn

Insider Shapiro David

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 30,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders.

Key Figures

Option grant size: 30,000 options Exercise price: $10.55 per share Expiration date: June 8, 2036 +2 more

5 metrics

Option grant size 30,000 options Stock Option (right to buy) granted to director David Shapiro

Exercise price $10.55 per share Conversion or exercise price for the stock options

Expiration date June 8, 2036 Option expiration for the 30,000-share grant

Underlying shares 30,000 shares Underlying common stock covered by the option grant

Vesting period 12 months after June 9, 2026 Equal monthly vesting with full vesting by next annual meeting

Key Terms

Stock Option (right to buy), exercise price, vest in equal monthly installments, annual meeting of stockholders

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 10.5500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in equal monthly installments financial

"The shares subject to the option vest in equal monthly installments over 12 months"

annual meeting of stockholders financial

"fully vested on the date of the Company's next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did David Shapiro receive in this Design Therapeutics (DSGN) Form 4 filing?

David Shapiro received a stock option grant for 30,000 shares of Design Therapeutics common stock. The options are a compensation award, giving him the right to buy shares at a fixed exercise price if he chooses in the future.

What is the exercise price of David Shapiro’s Design Therapeutics stock options?

The stock options have an exercise price of $10.55 per share. This means Shapiro can buy up to 30,000 shares at $10.55 each, regardless of the market price, once the options vest and before they expire in 2036.

How do David Shapiro’s Design Therapeutics options vest over time?

The options vest in equal monthly installments over 12 months following June 9, 2026. This monthly vesting schedule gradually makes more options exercisable and aligns Shapiro’s long-term incentives with the company’s performance over that year.

When will David Shapiro’s Design Therapeutics options be fully vested at the latest?

All 30,000 option shares will be fully vested by the date of Design Therapeutics’ next annual meeting of stockholders. This provision ensures full vesting even if the monthly vesting schedule would otherwise extend beyond that meeting date.

When do David Shapiro’s Design Therapeutics stock options expire?

The options expire on June 8, 2036. After that date, any unexercised options become worthless. The long expiration term gives Shapiro many years to decide if and when to exercise, depending on Design Therapeutics’ share price and his plans.

Does this Design Therapeutics Form 4 show David Shapiro buying or selling shares?

The filing reports a stock option grant, not an open-market trade. Shapiro acquired the right to buy 30,000 shares at $10.55, but no common shares were bought or sold in the market in this transaction; it is a compensation-related award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shapiro David

(Last) (First) (Middle)

C/O DESIGN THERAPEUTICS, INC.

6005 HIDDEN VALLEY ROAD, SUITE 110

(Street)

CARLSBAD CALIFORNIA 92011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Design Therapeutics, Inc. [ DSGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$10.55	06/09/2026		A		30,000		(1)	06/08/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders.

	/s/ Mustapha Parekh, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)